Galena Biopharma, Inc. (NASDAQ:GALE)

Stock Price

Biostage, Fossil Group Tumble into Friday’s 52-Week Low Club

February 10, 2017: Here are four stocks trading with relatively heavy volume among 27 equities making new 52-week lows in Friday's session. On the NYSE, advancers led decliners more than 2 ...
Read Full Story »
Stock Price

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

February 8, 2017: Here are four stocks trading with relatively heavy volume among 69 equities making new 52-week lows in Wednesday's session. On the NYSE, advancers led decliners by less than ...
Read Full Story »
Prescription Drugs, Pills

Wednesday’s Biggest Biopharma Movers

Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss. Although ...
Read Full Story »
Stock Price

DryShips, Stage Stores Plunge into Monday’s 52-Week Low Club

January 9, 2017: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday's session. On the NYSE, decliners led advancers by more ...
Read Full Story »
FDA_logo

Galena Rises on FDA Approval

Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA) approval. The company announced that it has confirmed the regulatory ...
Read Full Story »
FDA_logo

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

U.S. Food and Drug Administration (FDA) rulings and the results from clinical trials have proven time and again that they can make or break companies. The biotech and pharmaceutical companies ...
Read Full Story »
hammered

4 Companies That Destroyed Shareholders Despite a Brexit Recovery

Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to believe that this was just one big head fake. Some ...
Read Full Story »
Female patient on gurney

Is Galena Dead in the Water After This Failed Trial?

Galena Biopharma, Inc. (NASDAQ: GALE) is absolutely crashing on Wednesday after the company released further information regarding its Breast Cancer clinical trial. The company announced the recommendation from the Independent ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
buy sell

Top Wall Street Analyst Sell Ratings on High Profile Stocks This Week

At 24/7 Wall Street we have been running weekly research screens to scan the brokerage firms we cover for the stocks that are cut to Underperform or Sell ratings. The ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: BlackBerry, Care.com, Lululemon, Tesla, Veeco and More

Earnings season is now in the final phases, and investors and analysts are positioning themselves for the rest of 2014. Each morning, 24/7 Wall St. reviews dozens of Wall Street ...
Read Full Story »
$5

Eight Biotech Stocks Trading Near $5 With Huge Upside Potential

Often when a strong sell-off hits the stock market, the first stocks to go are the big momentum stocks that hedge funds often chase for performance and alpha. Right behind ...
Read Full Story »
buy sell

Ten Top Wall Street Analyst Stocks to Buy Trading Just Above or Below $5

Every quarter we like to review the research at the top firms we cover and look for any new stocks to buy that are priced either slightly above or under ...
Read Full Story »
biotech

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Large cap biotech stocks have seen incredible stock performance over the past few years. The problem for many investors is that many of the key stocks have become so expensive ...
Read Full Story »
ten bucks

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

With less than a week left in what has been the best year for the S&P 500 since 1997, we have reviewed our top Wall Street firms for their stocks ...
Read Full Story »